Company profile-
Alkem laboratory is a multinational pharmaceutical company
head quartered in Mumbai, Maharastra, established in 1973 by Mr.
Samprada Singh. Alkem has been ranked amongst the top ten
pharmaceutical companies in India in terms of domestic sales for the
past 15 years.
ALKEM LABOROTORY
Company type Public company
Industry Pharmaceuticals
Industry sector Biotechnology
Founded 1973
Founder Samprada Singh
Head quarter Mumbai, Maharashtra
products Pharmaceuticals , generic drug
Kind of products Acute and Chronic
Revenue ( Acc to Mar- 2019) 1467.84 Cr
Other income( Acc to Mar- 2019) 19.07 Cr
Operating income( Acc to Mar- 1486.91 Cr
2019)
Total asset( Acc to Mar- 2015) 4175 Cr
Total liability (Acc to Mar 2015) 2825 Cr
Total equity( Acc to Mar- 2015) 1350 Cr
CEO Prabhat Agrawal
Number of employees( Acc to Mar- 15,000
2015)
This Indian pharmaceutical company manufactures and sells
high quality pharmaceutical generics, active pharmaceutical
ingredient(APIs) formulations and neutraceutricals both in India and
internationally in 55 countries (mainly in US) including Australia ,
Europe, South East Asia, Latin America, Africa and CIS with a
comprehensive portfolio of over 750 brands and a robust pan-India
sales and distribution network.
The company has a wide ranging presence in the acute and
chronic therapeutic segments such as anti infectives, Gastrointestinal,
pain management, vitamins, minerals and nutrition , Central Nervous
System, anti-diabetic, anti-oteoporesis, anti-malarial, cardiovascular,
immunosuppressants and Nutraceutical segments. We are currently
ranked the sixth largest pharmaceutical company in India in terms of
domestic sales for the fiscal year 2018 with our iconic brands like
Clavam, Pan, Pan-D, Taxim and Taxim-O featuring amongst the top
50 pharmaceutical brands in India. Our International business
contributed about 28% to our overall revenues in fiscal year 2018
and is one of the important growth drivers for the company.
Ranked 5 in the Indian pharmaceutical market in terms of
domestic sales in the fiscal year 2015, the company enjoys a
domestic market leadership in the following segments
Ranked 1 in anti-infectives, with an 11.2% market share
Ranked 3 in gastro-intestinals with a 5.6% market share
Ranked 3 in pain/analgesics with a 5% market share
Ranked among the top 10 in vitamins, minerals, nutrients and
gynecology
Alkem Laboratories Limited is listed on the National Stock
Exchange of India (NSE) and the Bombay Stock Exchange
(BSE).
Manufacturing Facilities
We own and operate 14 manufacturing facilities across five locations
in India and two manufacturing facilities in the United States. In
order to serve our domestic and international markets, we own and
operate formulation and API manufacturing facilities which have
been built in accordance with the WHO cGMP guidelines. Each of our
manufacturing facilities has separate quality control units to monitor
the manufacturing quality of our products. Of the 14 facilities, our
facilities at Ankleshwar and Mandwa are API manufacturing facilities.
The remaining facilities, including those at Daman, Baddi and Sikkim,
manufacture formulations.
Our manufacturing facilities are inspected and audited as per cGMP
guidelines as laid down by leading regulatory authorities including
the US FDA, World Health Organization (WHO), MHRA (UK), TGA
(Australia), ANVISA (Brazil) and MCC (South Africa).
Quality Control-
In line with our quality policy, we have set up quality functions across
the organization to consistently monitor the process operations for
assuring the quality, safety and efficacy of our products in the
domestic and export markets. Our Quality Management Systems
(QMS) complies with various international regulatory and cGMP
standards and we perform periodic reviews of systems, practices and
documentation in place across our manufacturing facilities through
regular audits.
All products are subjected to extensive stability testing programs to
understand the real product behaviour during shelf life. We also
monitor in-market product quality through annual product quality
review mechanisms.
We believe that all our manufacturing facilities possess adequate
effluent treatment processes and minimize any contamination of the
surrounding environment or pollution. All these environment
protection systems are laid down as per the statutory requirements
of applicable laws and environmental policies.
2015
Successfully completed Intial Public Offering
2015
Acquired a formulation manufacturing facility in the US.
2014
Clavam crossed Rs. 2,000 million in terms of domestic sales in
India.
2014
Acquired the “Clindac-A” brand in India from Galderma S.A.
2013
Acquired an API manufacturing facility in the US.
2012
Acquired an API Manufacturing facility in the US.
2011
Acquired Enzene, a company engaged in the development of
biosimilars in India.
2010
Acquired Ascend Laboratories, a generic marketing company
in the US.
2009
Acquired Pharmacor Pty Ltd., a generic pharma company in
Australia.
2009
Received our first ANDA approval in US for Amlodipine.
2007
Filed our first ANDA in the US for the drug Amlodipine.
2006
Our anti-infective drug Taxim became the first anti-infective
drug in the Indian
pharmaceutical industry to cross Rs. 1,000 million in terms of
domestic sales in India.
2003
Set up our research and development facility for ANDA
development at Taloja.
1992
Established manufacturing facility in Mandva, Gujarat.
This facility was converted into an API facility in 2005.
1978
Established our first plant at Taloja, Mumbai
1973
Alkem Laboratories Limited was incorporated
Board of Directors
Mr. Samprada Singh
Chairman Emeritus
Mr. Samprada Singh is one of the co-founders of the Company
and an industry veteran with over 43 years of experience in
Indian pharmaceutical industry. He has received various
prestigious awards such as the ‘Life Time Achievement Award’
by Pharma Business and Technology in 2000, the ‘Lifetime
Achievement Award’ at the Pharmaceutical Leadership Summit
2009, ‘Asian Grid Leadership Lifetime Achievement Award
2006’, the ‘Life Time Contribution Award’ by the Express
Pharma Excellence Awards in 2004 and ‘Lifetime Achievement
Award’ at the 2nd Annual AWACS Awards in Marketing
Excellence, 2015. He was also bestowed with the EY
Entrepreneur of the Year Award in Life Sciences for the year
2016. Recently he was awarded with the Bihar Pride Achiever
2017 Award at Rising Bihar 2017 summit and the Global Asian
of the Year 2017 by Indian Singapore Business & Social Forum
2018.
Mr. Basudeo N. Singh
Executive Chairman
Mr. Basudeo N. Singh has almost four decades of experience in
the Indian pharma sector and is also the co-founder of the
Company. He was the President of the Indian Drug
Manufacturer’s Association for the period 2007-09. He has
received Business Leader of the Year 2014 award at the 7th
Annual Pharmaceutical Leadership Summit and Pharma
Leaders Business Leadership Awards 2014. He was bestowed
with the EY Entrepreneur of the Year Award in Life Sciences for
the year 2016. Recently he was also awarded with the Chief
Mentor of the Year award by Indian Drug Manufacturer’s
Association.
Mr. Sandeep Singh
Managing Director
Mr. Sandeep Singh joined the Board in 2013 and at present is
the Managing Director of the Company. He has an experience
of over 10 years in the pharmaceutical industry. Mr. Sandeep
Singh is responsible for both domestic as well as international
operations of the Company. He was honoured with the
Emerging Pharma Leader of 2016 award by Pharma Leaders in
association with the Ministry of Health & Family Affairs,
Government of India.
Mr. Dhananjay Kumar Singh
Joint Managing Director
Mr. Dhananjay Kumar Singh joined the Board in the year 1988
and at present is the Joint Managing Director of the Company.
He has over 30 years of experience in the Indian
pharmaceutical industry. Mr. Dhananjay Kumar Singh heads
the Bergen, Arise, Forgen and Pharma divisions of the
Company’s domestic business. He also heads the Distribution &
Logistics, Purchases, Commercials, Human Resource, Legal,
Secretarial & Compliance departments of the Company.
Mr. Balmiki Prasad Singh
Executive Director
Mr. Balmiki Prasad Singh joined the Board in 1988. Prior to
being appointed as a member of the Board, he was employed
with the Company in various other capacities. He has over 30
years of experience in the Indian pharmaceutical industry. He
heads the Generics and OTC business of the Company.
Mr. Mritunjay Kumar Singh
Executive Director
Mr. Mritunjay Kumar Singh joined the Board in 1988 and he
has been associated with the management of the Company for a
period over 24 years. He is also the Managing Director of the
Company’s subsidiary, Indchemie Health Specialities Private
Limited. Mr. Mritunjay Kumar Singh heads Alpha, Ace,
Cytomed and Hospicare divisions of the Company’s domestic
business. Additionally he looks after the Formulations Facility,
Marketing and Sales, Business Development & Strategy and
Production Planning for the domestic business of the Company.
Mr. Arun Kumar Purwar
Independent Director
Mr. Arun Kumar Purwar joined the Board in 2015. Mr. Purwar
in the past has served as the Chairman of State Bank of India
from November 2002 to May 2006. Mr. Purwar was the
Chairman of Indian Bank Association during 2005-06. He has
received various prestigious awards such as the ‘CEO of the
Year’ Award from the Institute of Technology and Management
in 2004, ‘Outstanding Achiever of the year’ award from the
Indian Banks’ Association in 2004 and ‘Finance Man of the
Year’ award by the Bombay Management Association in 2006.
He is a Director in various leading companies in Power,
Telecom, Steel, Tyres and Financial services sector.
Mr. Ranjal Laxmana Shenoy
Independent Director
Mr. Ranjal Laxmana Shenoy joined the Board in 2015. Mr.
Shenoy has over 40 years of working experience with
companies in different industrial segments, including the
position of Whole Time Director – Finance and Legal and
Company Secretary, in Merck Limited, India, (formerly known
as E. Merck (India) Limited). He is a qualified Chartered
Accountant, Cost Accountant and Company Secretary. Mr.
Shenoy also holds a Bachelor’s degree in Law from University of
Mysore and a Masters’ degree in Law from Mumbai University.
He is also an Associate Member of the Indian Institute of
Bankers ([Link]).
Mr. Akhouri Maheshwar Prasad
Independent Director
Mr. Akhouri Maheshwar Prasad joined the Board in 2015. Mr.
Prasad has served the Government of India in the Indian
Revenue Service for 37 years. He has held several key positions
in the Government including Special Secretary to GoI and
Director General, Central Economic Intelligence Bureau,
Member of the Central Board of Excise and Customs, Chief
Commissioner, Central Excise and Customs, Maharashtra.
Ms. Sangeeta K. Singh
Independent Director
Ms. Sangeeta Singh joined the Board in 2015. She is an
Independent Director on several renowned company Boards
and has over 35 years of experience in Human Resources,
Communications and Operations. She was Partner & Head of
Human Resources for KPMG India. She has a Masters degree in
Behavioural Psychology and a certification in Strategic Human
Resource Management from Harvard Business School.
Ms. Sudha Ravi
Independent Director
Ms. Sudha Ravi joined the Board in 2015. She is presently
working with Piramal Capital & Housing Finance Ltd., the
merged entity of Piramal Finance Ltd. with Piramal Housing
Finance Ltd. Since October 2014, she is additionally in-charge
of India Venture Advisors Pvt. Ltd. – a healthcare and life
sciences focused private equity fund sponsored by the Piramal
Group. Prior to joining Piramal Group in 2011, Ms. Ravi was
with State Bank of India (SBI) for over 30 years, having joined
SBI as a direct recruit Probationary Officer in 1978. In her
extensive service in SBI, she has held various important
portfolios and has had the opportunity of working in metro,
urban and rural areas across the length and breadth of the
country. She has worked in varied functional areas at SBI
including International, Corporate, Retail and Rural banking
which has given her a wideranging perspective on the financial
sector and business strategy. She has held key positions like
General Manager, Enterprise Risk Management facilitating
alignment of risk with strategy at the Bank-wide level and as
Chief Representative, Washington DC, US. She has received
recognition(s)/plaques presented by the Indian Associations in
US for outstanding contribution in the sphere of banking for
the community in Washington DC. Ms. Ravi has keen interest
in Special Education with focus on education for autistic
children.
Dr. Dheeraj Sharma
Independent Director
Dr. Dheeraj Sharma joined the Board in May 2017. He holds a
doctoral degree with a major in marketing and a double minor
in psychology and quantitative analysis from Louisiana Tech
University. His primary research interests are ‘relationships’ in
business domain. He is a Director at Indian Institute of
Management – Rohtak and a Professor (on lien) at Indian
Institute of Management – Ahmedabad. He has also served as
consultant or in advisory roles with Ministry of Home Affairs,
Ministry of Defence, Ministry of Youth Affairs and Sports,
Ministry of Commerce, Govt. of Gujarat, Govt. of Punjab and
Govt. of Delhi.
Extended Life
Research & Development
Alkem’s research and development department carries out
process development, formulation development and analytical
research for our domestic and international markets.
This company have a 120-bed clinical research organization
facility where they conduct bioequivalence and bioavailability
studies on healthy volunteers to prove the effectiveness of
developed formulations relative to reference products in
accordance with the regulatory guidelines of various regulatory
agencies. This facility has been audited by the USFDA, UK-
MHRA and other regulatory agencies.
This organization believe that their continuing research and
development initiatives have strengthened their product
offering in India, the United States and other international
markets. Alkem have a strong pipeline of products under
development for our focus markets.
Mar 2018 Mar 2017 Mar 2016 Mar 2015 Mar 2014 Mar 2013
Particulars
( ).Cr ( ).Cr ( ).Cr ( ).Cr ( ).Cr ( ).Cr
SOURCES OF
FUNDS :
Share Capital 23.91 23.91 23.91 23.91 11.96 11.96
Reserves Total 4861.45 4368.74 3575.59 3077.11 2703.00 2290.78
Equity Share 0.00 0.00 0.00 0.00 0.00 0.00
Warrants
Equity 0.00 0.00 0.00 0.00 0.00 0.00
Application
Money
Total 4885.36 4392.65 3599.50 3101.02 2714.96 2302.74
Shareholders
Funds
Secured Loans 110.71 108.00 151.06 883.24 730.47 923.58
Unsecured Loans 436.81 260.23 229.21 219.30 216.60 305.88
Total Debt 547.52 368.23 380.27 1102.54 947.07 1229.46
Total Liabilities 5432.88 4760.88 3979.77 4203.56 3662.03 3532.20
APPLICATION OF
FUNDS :
Gross Block 1713.69 1262.90 944.72 1156.17 909.39 832.06
Less : 242.70 137.27 70.04 285.71 0.00 0.00
Accumulated
Depreciation
Mar 2018 Mar 2017 Mar 2016 Mar 2015 Mar 2014 Mar 2013
Particulars
( ).Cr ( ).Cr ( ).Cr ( ).Cr ( ).Cr ( ).Cr
Less:Impairmen 0.00 0.00 0.00 0.00 0.00 0.00
t of Assets
Net Block 1470.99 1125.63 874.68 870.46 909.39 832.06
Lease 0.00 0.00 0.00 0.00 0.00 0.00
Adjustment
Capital Work in 298.92 218.44 146.55 95.89 0.00 0.00
Progress
Producing 0.00 0.00 0.00 0.00 0.00 0.00
Properties
Investments 1544.50 1517.64 1157.67 1070.56 939.99 579.41
Current Assets,
Loans &
Advances
Inventories 1024.16 858.76 590.03 548.24 504.56 452.80
Sundry Debtors 875.00 633.32 480.44 375.01 290.32 291.81
Cash and Bank 278.30 199.06 524.03 633.32 122.76 965.18
Loans and 513.15 284.89 211.98 160.81 152.96 216.71
Advances
Total Current 2690.61 1976.03 1806.48 1717.38 1070.60 1926.50
Assets
Less : Current
Liabilities and
Provisions
Current Liabilities 1143.03 941.16 684.39 461.99 397.96 335.33
Provisions 102.46 103.96 89.63 66.65 50.16 46.25
Total Current 1245.49 1045.12 774.02 528.64 448.12 381.58
Liabilities
Net Current 1445.12 930.91 1032.46 1188.74 622.48 1544.92
Assets
Mar 2018 Mar 2017 Mar 2016 Mar 2015 Mar 2014 Mar 2013
Particulars
( ).Cr ( ).Cr ( ).Cr ( ).Cr ( ).Cr ( ).Cr
Miscellaneous 0.00 0.00 0.00 0.00 0.00 0.00
Expenses not
written off
Deferred Tax 759.87 753.12 555.95 29.20 34.02 20.32
Assets
Deferred Tax 181.82 162.12 146.56 97.71 78.08 68.36
Liability
Net Deferred Tax 578.05 591.00 409.39 -68.51 -44.06 -48.04
Total Assets 5337.58 4383.62 3620.75 3157.14 2427.80 2908.35
Contingent 277.30 310.82 684.87 354.94 341.97 479.95
Liabilities
Histotry-
Alkem Laboratories Ltd was incorporated as a private limited
company on August 8, 1973 at Patna under the Companies Act,
1956 and subsequently became a deemed public limited
company under section 43A(2) of Companies Act, 1956 on
October 26, 1988. Pursuant to our Company passing a
resolution under section 21 of Companies Act, 1956 and upon
issuance of a fresh certificate of incorporation consequent on
change of name dated August 21, 2001, the name of our
Company was changed to Alkem Laboratories Limited' with
effect from October 26, 1988.
In 1978, the company established its first plant at Taloja
Maharashtra. In 1992, the company established its
manufacturing facility in Mandwa, Maharashtra, which was
later converted into an API facility in 2005. In 2003, the
company set up a research and development facility for ANDA
development at Taloja, Maharashtra.
During the year 2006, the company's anti-infective drug Taxim
became the first anti-infective drug in the Indian
pharmaceutical industry to cross Rs 100 crore in terms of
domestic sales in India. In 2007, the company filed its first
ANDA in the US for the drug Amlodipine. In 2009, the
company received first ANDA approval in US for Amlodipine.
Also during the year, the company acquired Pharmacor Pty
Ltd., a generic pharma company in Australia.
In 2010, Alkem Laboratories acquired Ascend Laboratories, a
generic marketing company in the US. In 2011, the company
acquired Enzene, a company engaged in the development of
biosimilars in India. In 2012, the company acquired an API
manufacturing facility in the US.
In 2014, the company acquired the 'Clindac-A' brand in India
from Galderma S.A. Also during the year, Clavam crossed Rs
200 crore mark in terms of domestic sales in India. In 2015, the
company acquired a formulation manufacturing facility in the
US.
On 23 December 2015, Alkem Laboratories successfully
completed an Initial Public Offering (IPO) with its equity shares
listed on the Bombay Stock Exchange Limited and the National
Stock Exchange of India Limited.
On 10 May 2016, Alkem Laboratories announced that the
Competition Appellate Tribunal (COMPAT) has passed an
order dated 10 May2016 setting aside the penalty of Rs 74.63
crore imposed on the company by the Competition Commission
of India (CCI) in its order dated 1 December 2015.
On 7 June 2016, Alkem Laboratories announced the closure of
the inspection by the United Kingdom - The Medicines and
Healthcare Products Regulatory Agency (UK-MHRA) for its
Bioequivalence facility at Taloja, Maharashtra, India. The
facility stands UK-MHRA compliant.
On 11 August 2016, Alkem Laboratories announced that the
USFDA inspected the company's Bioequivalence facility at
Taloja, Maharashtra, India from 1 August to 10 August 2016. At
the end of the inspection, there were no 483s issued by the
USFDA.
On 28 October 2016, Alkem Laboratories announced that the
USFDA conducted a Bio-analytical inspection at the company's
manufacturing facility located at Daman, India from 24 October
to 28 October 2016. The inspection has been cleared
successfully without any 483 observations. This inspection was
based on an ANDA filed by the company.
On 7 February 2017, Alkem Laboratories announced that it has
entered into an alliance with Haw Par India Pvt Ltd., a wholly
owned subsidiary of Haw Par Healthcare Ltd., Singapore to
exclusively market, sell and distribute Tiger Balm range of
products in India. Tiger Balm products will be promoted by
Alkem Healthcare, an Over the Counter (OTC) division of
Alkem. Tiger Balm range of products is an internationally
known remedy for headaches, upper respiratory congestions,
rheumatic or arthritic pains and muscular sprains. Its unique
blend of herbal ingredients, derived from an ancient Chinese
source, has been proven effective for nearly 100 years and is
trusted by millions of people in more than 100 countries.
On 29 March 2017, Alkem Laboratories announced that the
USFDA has issued an Establishment Inspection Report (EIR)
for its Ankaleshwar API facility which was inspected in
December 2016. The inspection has now been closed by the
USFDA. The USFDA had inspected the Ankaleshwar API
manufacturing facility from 5 to 9 December 2016 and had
issued Form 483 with three observations. Post this, the
company had submitted a detailed corrective and preventive
action plan (CAPA) to the regulator within the stipulated
timelines. The USFDA has reviewed the CAPA and has found
them acceptable.
On 10 January 2018, Alkem Laboratories announced the
closure of USFDA inspection at its Baddi facility in Himachal
Pradesh.
On 28 March 2018, Alkem Laboratories informed the stock
exchanges that the USFDA conducted an inspection at the
company's manufacturing facility located at Amaliya, Daman,
India from 19 March 2018 to 27 March 2018. Post the
inspection, the company has received a Form 483 with thirteen
observations. The company said it will put together a detailed
response with adequate corrective and preventive measures to
address the USFDA observations within the timeline stipulated
by the USFDA. The USFDA also conducted an inspection at the
company's manufacturing facility located at St. Louis, USA
from 12 March 2018 to 16 March 2018. In response to the one
Form 483 observation issued by the USFDA, the company has
submitted a detailed corrective and preventive action plan
(CAPA) plan to the regulator within the stipulated timelines.
Milestones
1973 – Starts operations as a healthcare marketing company
1978
o Establishes first plant at Taloja, Mumbai
o Alkem Laboratories Limited is incorporated
1992 – Establishes manufacturing facility in Mandura,
Maharashtra (converted into an API facility in 2005)
2003 – Sets up an in-house R&F facility for ANDA
development at Taloja
2006 – Taxim becomes the first anti-infective drug in the
Indian pharmaceutical industry to cross INR 1,000 million in
domestic sales
2007 – Files first ANDA in the US for the Amlodipine
2009 – Acquires Australian generic pharma company,
Pharmacor Pty Ltd.,
2009 – Receives first ANDA approval in US for Amlodipine
2010 – Acquires US generic marketing company, Ascend
Laboratories
2011 – Acquires Enzene, an Indian company engaged in the
development of biosimilars
2012 – Acquires an API manufacturing facility in the US
2013 – Acquires another API manufacturing facility in the US
2014 – Clavam crosses INR 2,000 million in domestic sales in
India
2014 – Acquires the “Clindac-A” brand in India from Galderma
S.A.
2015 – Acquires a formulation manufacturing facility in the US
2016- Samprada Singh and Basudev Singh were bestowed with “EY
Enterpreneur of the year award” in life sciences. Alkem won the HR
Tech award for best use of technology in Human Resource” by
world HRD Congress. Alkem won the best demand and forecasting
company pharmaceutical by ICSM’s in demand planning and forecast
forum award 2016. Alkem won the Guinness World Record for
creating largest Blister pack Mosaic at RSSDI Hyderabad.
2017- Alkem receive the best standard out IR award 2017 by IR
Society India in association with KPMG and Bloomberg. Alkem
won the People Matter League award Learning and
Development 2017- Best in cultural transformation in Mumbai.
Alkem won the Rising Digital Star of the year for various digital
initiatives and won the most enterprising company for
Leveraging technology for learning and development by
DigiPharmaX Award 2017.
2018- Samprada Singh was honoured with Prestigious Global
Asian of the year award 2017 at Singapore Business and Social
Forum 2018 held at Singapore by Asian One Magazine and URS
Media and Basudev Narayan Singh was conferred with the cjief
Mentor of the year award 2017 by Indian Drug Manufacturer
Association during with their 56th Annual day celebration.
